[Pulmonary hypertension: microRNAs in pathogenesis, diagnosis and therapy]
- PMID: 24715431
- DOI: 10.1055/s-0034-1365456
[Pulmonary hypertension: microRNAs in pathogenesis, diagnosis and therapy]
Abstract
Whereas pulmonary arterial hypertension is an orphan disease, the term pulmonary hypertension includes several common entities and is of major clinical significance. The pathophysiological triad of vasoconstriction, microthrombosis and vascular remodeling is found in most forms of pulmonary hypertension, independently of the underlying etiology. In this review, novel aspects in the pathogenesis of the remodeling, in particular microRNAs, will be discussed. MicroRNAs are small RNA fragments which bind specifically to the mRNA of a target gene thus decreasing its stability or inhibiting further translation ("gene silencing"). Of major interest is the association between microRNAs and the expression of bone morphogenetic protein receptor type II which has been found to be dysregulated on pulmonary endothelial and vascular smooth muscle cells in several forms of pulmonary hypertension. The specific inhibition of microRNAs by antagomiRs makes microRNAs a potential therapeutic target. Moreover, microRNAs are being validated in serum as biomarkers for diagnosis, severity and prognosis of pulmonary hypertension.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension.Expert Opin Ther Targets. 2013 May;17(5):557-64. doi: 10.1517/14728222.2013.765863. Epub 2013 Feb 2. Expert Opin Ther Targets. 2013. PMID: 23379818 Review.
-
Genetic Delivery and Gene Therapy in Pulmonary Hypertension.Int J Mol Sci. 2021 Jan 25;22(3):1179. doi: 10.3390/ijms22031179. Int J Mol Sci. 2021. PMID: 33503992 Free PMC article. Review.
-
Pulmonary hypertension: biomarkers.Handb Exp Pharmacol. 2013;218:77-103. doi: 10.1007/978-3-642-38664-0_4. Handb Exp Pharmacol. 2013. PMID: 24092337 Review.
-
Pulmonary arterial hypertension and microRNAs--an ever-growing partnership.Arch Med Res. 2013 Oct;44(7):483-7. doi: 10.1016/j.arcmed.2013.08.003. Epub 2013 Sep 17. Arch Med Res. 2013. PMID: 24051036 Review.
-
Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.Exp Mol Med. 2015 Jul 31;47(7):e175. doi: 10.1038/emm.2015.45. Exp Mol Med. 2015. PMID: 26228095 Free PMC article. Review.
Cited by
-
Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study.Trials. 2019 Dec 16;20(1):725. doi: 10.1186/s13063-019-3770-0. Trials. 2019. PMID: 31842950 Free PMC article.
-
Pathogenesis of pulmonary hypertension caused by left heart disease.Front Cardiovasc Med. 2023 Mar 3;10:1079142. doi: 10.3389/fcvm.2023.1079142. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36937903 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
